Diana Franklin
Primary Care · Jackson, MINPI 1417542200
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,236, 3.5 times the $356 reported in 2021. Among primary care clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$606
- GSK$442
- Inspire Medical Systems, Inc.$433
- Sanofi$300
- Actelion Pharmaceuticals US, Inc.$245
- Harmony Biosciences LLC$181
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,40298%
- Education$802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $606 |
| GSK | 28 | $442 |
| Inspire Medical Systems, Inc. | 16 | $433 |
| Sanofi | 12 | $300 |
| Actelion Pharmaceuticals US, Inc. | 7 | $245 |
| Harmony Biosciences LLC | 8 | $181 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $174 |
| United Therapeutics Corporation | 5 | $121 |
| Boehringer Ingelheim | 5 | $104 |
| Grifols USA, LLC | 4 | $101 |
| Regeneron Healthcare Solutions, Inc. | 4 | $89 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Merck | 3 | $76 |
| Mylan Specialty L.p. | 3 | $67 |
| AbbVie | 4 | $63 |
| Insmed, Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Genentech USA, Inc. | 2 | $38 |
| UCB, Inc. | 2 | $38 |
| Electromed, Inc. | 2 | $32 |
| Viatris Specialty LLC | 2 | $30 |
| Baxter Healthcare | 1 | $30 |
| Vanda Pharmaceuticals Inc. | 2 | $25 |
| 3b Medical, Inc. | 4 | $23 |
| ZOLL Respicardia, Inc. | 1 | $19 |
| Indivior Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| Novo Nordisk | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,482 in reported general payments places this provider in the 90th percentile of 292 primary care providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $79,134 |
| Spiriva RespimatTiotropium Bromide | 18 | $14,870 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $14,135 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,548 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $7,053 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 117 | $6,031 |
| Ventolin HfaAlbuterol Sulfate | 48 | $2,878 |
| Montelukast Sodium | 100 | $977 |
| Azithromycin | 53 | $782 |
| Ipratropium Bromide | 13 | $467 |
| Fluticasone Propionate | 16 | $259 |
| Prednisone | 29 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $442 | $93,26997 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $104 | $21,92329 claims |
| AstraZenecaBreztri Aerosphere | $606 | $8,54814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 292 primary care providers in Michigan.
Other primary care in Jackson
- Jaleesa AtkinsJackson$2K
- Donna HamillGrosse Pointe$17K
- Marie Sighe-NzokouLansing$16K
- Alexandria SchwabBay City$10K
- Amy HenryRochester Hills$10K
- Claire GebaraWaterford$9K
- Vanita RobinsonDetroit$9K
- Mary BoudreauMason$9K
- Kimberly FrazierLansing$8K
- Rachel HetznerMadison Heights$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.